You can help our author matching system! If you notice any publications incorrectly attributed to this author, please
sign in and mark matches as correct or incorrect.
|
Morgan WJ, VanDevanter DR, Pasta DJ, et al. (2023) Corrigendum to FEV1 Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function [The Journal of Pediatrics (2016) 116-121]. The Journal of Pediatrics |
Sawicki GS, Konstan MW, McKone EF, et al. (2022) Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. Pulmonary Therapy |
Endres TM, Konstan MW. (2022) What Is Cystic Fibrosis? Jama. 327: 191 |
Elborn JS, Konstan MW, Taylor-Cousar JL, et al. (2021) Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society |
Sawicki GS, Van Brunt K, Booth J, et al. (2021) Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society |
Bilton D, Fajac I, Pressler T, et al. (2021) Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society |
Konstan MW, Pasta DJ, VanDevanter DR, et al. (2021) Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatric Pulmonology |
VanDevanter DR, Hamblett NM, Simon N, et al. (2020) Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society |
Konstan MW, VanDevanter DR, Rowe SM, et al. (2020) Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society |
Chiron R, Elborn JS, Flume P, et al. (2020) ePS3.10 Patient demographics and baseline disease characteristics in a multicentre, randomised, double-blind, placebo-controlled phase 2b study of lenabasum, a selective cannabinoid receptor type 2 agonist, in cystic fibrosis Journal of Cystic Fibrosis. 19 |